Search results
Results from the WOW.Com Content Network
Late gadolinium enhancement (LGE) and T1 mapping allow infarction and fibrosis to be identified for characterizing cardiomyopathy and assessing viability. [8] Magnetic resonance angiography may be performed with or without contrast medium and is used to assess congenital or acquired abnormalities of the coronary arteries and great vessels. [9]
As a free solubilized aqueous ion, gadolinium(III) is highly toxic, but the chelated compounds are generally regarded as safe for individuals without kidney disease. Free Gd 3+ has a median lethal dose of 0.34 mmol/kg (IV, mouse) [27] or 100–200 mg/kg, but the LD50 is increased by a factor of 31 times [28] when Gd 3+ is chelated. [29]
The Lake Louise Criteria include increased signal intensity after gadolinium contrast enhancement (a sign of hyperemia, or increased blood flow to damaged tissue), increased myocardial T2 relaxation time or an increased T2 signal intensity (which are signs of tissue edema or swelling), and late gadolinium contrast enhancement (which is a sign ...
Delayed Gadolinium-enhanced MR Imaging of Articular Cartilage: Three-dimensional T1 Mapping with Variable Flip Angles and B1 Correction; Toward Imaging Biomarkers for Glycosaminoglycans; Longitudinal Evaluation of Cartilage Composition of Matrix-Associated Autologous Chondrocyte Transplants with 3-T Delayed Gadolinium-Enhanced MRI of Cartilage
It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd 3+), and is used in form of the meglumine salt (gadoterate meglumine). [ 4 ] [ 5 ] The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI , which is the source of its clinical utility.
Gadobutrol is a medicinal product used in diagnostic magnetic resonance imaging (MRI) in adults and children. It provides contrast enhancement during cranial, spinal, breast, or other investigations. In the central nervous system, Gadobutrol works by highlighting any areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity.
The contrast agents used for DCE-MRI are often gadolinium based. Interaction with the gadolinium (Gd) contrast agent (commonly a gadolinium ion chelate) causes the relaxation time of water protons to decrease, and therefore images acquired after gadolinium injection display higher signal in T1-weighted images indicating the present of the agent.
A 2015 study found gadolinium deposited in the brain tissue of people who had received gadodiamide. [8] Other studies using post-mortem mass spectrometry found most of the deposit remained at least 2 years after an injection and deposit also in individuals with no kidney issues. In vitro studies found it to be neurotoxic. [9]